Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.
Kokic, G., Hillen, H.S., Tegunov, D., Dienemann, C., Seitz, F., Schmitzova, J., Farnung, L., Siewert, A., Hobartner, C., Cramer, P.(2021) Nat Commun 12: 279-279
- PubMed: 33436624 
- DOI: 10.1038/s41467-020-20542-0
- Primary Citation of Related Structures:  
7B3B, 7B3C, 7B3D - PubMed Abstract: 
Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients. The active form of remdesivir acts as a nucleoside analog and inhibits the RNA-dependent RNA polymerase (RdRp) of coronaviruses including SARS-CoV-2. Remdesivir is incorporated by the RdRp into the growing RNA product and allows for addition of three more nucleotides before RNA synthesis stalls ...